Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone626-305-5900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40.60 million
Profitability
Miscellaneous
Employees156
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
Xencor (NASDAQ:XNCR) Frequently Asked Questions
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor Inc (NASDAQ:XNCR) posted its earnings results on Monday, November, 5th. The biopharmaceutical company reported $0.05 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.52) by $0.57. The biopharmaceutical company had revenue of $29.04 million for the quarter. View Xencor's Earnings History.
When is Xencor's next earnings date?
What price target have analysts set for XNCR?
9 equities research analysts have issued 1-year price objectives for Xencor's shares. Their forecasts range from $21.00 to $56.00. On average, they anticipate Xencor's stock price to reach $41.8722 in the next twelve months. This suggests a possible upside of 33.5% from the stock's current price. View Analyst Price Targets for Xencor.
What is the consensus analysts' recommendation for Xencor?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.
What are Wall Street analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $40 price target. We think Xencor’s collaboration and license agreement with Astellas (ALPMF, NC) marks another source of platform validation and pipeline income for the company. Xencor will develop and characterize bispecific candidates against an Astellas-selected oncology target. We do not know whether Astellas has chosen to develop a CD3 engaging bispecific but we view the agreement as another point of support to the the ongoing partial clinical hold on XmAb14045. From speaking to the company, the substantial high-single to low-double digit royalty is one of the highest for this type of technology access deal." (4/2/2019)
- 2. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (12/20/2018)
Has Xencor been receiving favorable news coverage?
News stories about XNCR stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xencor earned a news impact score of 1.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), TESARO (TSRO), Taro Pharmaceutical Industries (TARO) and HUTCHISON CHINA/S (HCM).
What other stocks do shareholders of Xencor own?
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
- Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
- Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
- Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
- Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations
Who are Xencor's major shareholders?
Xencor's stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.58%) and Equitec Specialists LLC (0.02%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.
Which institutional investors are buying Xencor stock?
How do I buy shares of Xencor?
Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of XNCR stock can currently be purchased for approximately $31.36.
How big of a company is Xencor?
Xencor has a market capitalization of $1.77 billion and generates $40.60 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Xencor employs 156 workers across the globe.
What is Xencor's official website?
How can I contact Xencor?
Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]
MarketBeat Community Rating for Xencor (NASDAQ XNCR)
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
